Showing 6701-6710 of 7490 results for "".
- Sculpsure Cleared to Treat Double Chinshttps://practicaldermatology.com/news/sculpsure-cleared-to-treat-double-chins/2458036/Cynosure's SculpSure® is now cleared for submental fat reduction. The U.S. Food and Drug Administration (FDA) granted an expanded FDA 510(k) clearance for this area, Hologic, Inc. reports.
- Castle Creek Pharmaceuticals Unveils First-Ever IGA Scale for EBS Clinical Researchhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-unveils-first-ever-iga-scale-for-ebs-clinical-research/2458035/Castle Creek Pharmaceuticals (CCP) has developed and validated the first Investigator's Global Assessment (IGA) scale to be used by clinicians evaluating the average overall severity of epidermolysis bullosa simplex (EBS) lesions in clinical tria
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad
- Dove: Women's Shower Routines May Do More Harm Than Goodhttps://practicaldermatology.com/news/dove-womens-shower-routines-may-do-more-harm-than-good/2458043/Close to 80 percent of dermatologists believe women often focus on facial skincare, but neglect body skincare, according to new research from Dove. What’s more, 69 percent of dermatologists report that many women use gentle facial c
- New Label Reflects Sustained Response for Sun Pharma's Odomzo in BCChttps://practicaldermatology.com/news/new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc/2458045/Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for t
- Eva Genel Named Director of Research and Development, Skincare at Silk Therapeuticshttps://practicaldermatology.com/news/eva-genel-named-director-of-research-and-development-skincare-at-silk-therapeutics/2458047/Eva Genel is the new Director of Research and Development, Skincare at Silk Therapeutics Inc., a specialty biomaterials company. In this new role, Genel's key responsibilities include designing and assessing clean, skincare formulations, o
- U.K Survey Reveals Eczema Treatment Knowledge Gaphttps://practicaldermatology.com/news/survey-reveals-eczema-treatment-knowledge-gap/2458049/Two thirds of UK eczema patients don’t understand that bacteria play a crucial role in their condition despite studies showing that Staphylococcus aureus is present on the skin in of more than 70 percent of patients, according to research from
- SkinCeuticals Launches Two New Cosmeceutical Cleansershttps://practicaldermatology.com/news/skinceuticals-launches-two-new-cosmeceutical-cleansers/2458048/SkinCeuticals is launching two new cleansers: Replenishing Cleanser and Smoothing Cleanser. What’s more, the original cleansers are all being repacked and reformulated. The new Replenishing Cleanser and Soothing Cleanser join SkinCeuticals&
- Happy 70th Cetaphil!https://practicaldermatology.com/news/happy-70th-cetaphil/2458051/Cetaphil is turning 70! To celebrate this milestone birthday, which takes place on Sept. 19, Cetaphil will launch a series of initiatives including: A 70-hour flash sale across retail partners nationwide running from September 17, 2017
- Five-Year Data Show Sustained Efficacy, Safety for Cosentyxhttps://practicaldermatology.com/news/five-year-data-show-sustained-efficacy-safety-for-cosentyx/2458054/Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for